A Phase 4 interventional study of Amlodipine besylate and Amlodipine besylate/atorvastatin calcium single pill combination in Dyslipidemia and Hypertension, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 51 sites in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-02-11.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Dyslipidemias by Viatris Inc. — none open to participants now, none under way, none of them phase 3. Dyslipidemias · Viatris Inc..
Among the 15 studies in Dyslipidemias by Viatris Inc., this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2007, is one of 11 in phase 4, and was the 4th registered.
1,250 studies on the registry are indexed under Dyslipidemias; 178 are open to participants now.
Browse Dyslipidemias studies →None of the 15 studies in Dyslipidemias by Viatris Inc. is open now. The open studies under Dyslipidemias, anywhere →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 245 is above the median of 100 across 987 interventional studies indexed under Dyslipidemias.
Median enrollment 361 across the 12 interventional studies, 4,386 across the 3 observational. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Dyslipidemias by Viatris Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood pressure and low density lipoprotein cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach (Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with hypertension and additional risk factors, including dyslipidemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Blinded amlodipine 5 mg and amlodipine/atorvastatin single pill combination 5/20 mg placebo dosed once daily for 6 weeks.
Drug: Amlodipine besylate
Blinded amlodipine/atorvastatin single pill combination 10/20 mg dosed once daily for 6 weeks and amlodipine besylate 10 mg placebo.
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Blinded amlodipine 19 mg and amlodipine/atorvastatin single pill combination 10/20 mg placebo dosed once daily for 6 weeks.
Drug: Amlodipine besylate
Blinded amlodipine/atorvastatin single pill combination 5/20 mg and amlodipine besylate 5 mg placebo dosed once daily for 6 weeks .
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Amlodipine besylate 5 mg
Amlodipine/atorvastatin single pill combination 10/20 mg
Amlodipine besylate 10 mg
Amlodipine/atorvastatin single pill combination 5/20 mg
Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6
Number of subjects reaching dual goal of systolic blood pressure \<140 millimeters of mercury (mmHg) and diastolic blood pressue of \<90 mmHg and low density lipoprotein-cholesterol(LDL-C) \<100 milligrams per deciliter(mg/dL)
Time frame: Week 6
Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk
Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \[MI\] or CHD death) are calculations based on total point score (range less than negative 3 \[best\] to greater than or equal to 14 \[worst\] for men; less than or equal to negative 2 \[best\] and greater than or equal to 17 \[worst\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.
Time frame: Week 6, baseline
Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4
Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of \<140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal \<100 mg/dL at Week 4.
Time frame: Week 4
Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4.
Subjects achieving both JNC-7 blood pressure goal of \<140/90 mmHg and NCEP/ATP III LDL-C goal \<130 mg/dL at Week 4.
Time frame: Week 4
Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6.
Subjects achieving both JNC-7 blood pressure goal of \<140/90 mmHg and NCEP/ATP III LDL-C goal \<130 mg/dL at Week 6.
Time frame: Week 6
Subjects With LDL-C < 100 mg/dL at Week 4
Subjects Who achieve a goal of LDL-C \< 100 mg/dL at Week 4.
Time frame: Week 4
Subjects With LDL-C < 100 mg/dL at Week 6
Subjects Who achieve a goal of LDL-C \< 100 mg/dL at Week 6.
Time frame: Week 6
Subjects With BP < 140/90 mmHg at Week 4
Subjects achieving BP goal of \<140/90 mmHg at week 4
Time frame: Week 4
Subjects With BP < 140/90 mmHg at Week 6
Subjects achieving BP goal of \<140/90 mmHg at week 6
Time frame: Week 6
Change From Baseline to Week 4 in Systolic Blood Pressure (SBP).
Mean at observation minus mean at baseline
Time frame: Week 4, baseline
Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP)
Mean at observation minus mean at baseline
Time frame: Week 4, baseline
Change From Baseline to Week 4 in Pulse Rate
Mean at observation minus mean at baseline measured in beats per minute (bpm).
Time frame: Week 4, baseline
Change From Baseline to Week 6 in Systolic Blood Pressure (SBP)
Mean change at observation minus mean baseline.
Time frame: Week 6, baseline
Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP)
Change from mean at observation minus mean at baseline
Time frame: Week 6, baseline
Change From Baseline to Week 6 in Pulse Rate
Mean at observation minus mean at baseline
Time frame: Week 6, baseline
Change From Baseline in LDL at Week 4.
Change: mean of observation minus mean at baseline.
Time frame: Week 4, baseline
Change From Baseline in High Density Lipoprotein (HDL) at Week 4.
Mean change at observation minus baseline.
Time frame: Week 4, baseline
Change in Total Cholesterol (TC) From Baseline to Week 4.
Mean change at observation minus baseline.
Time frame: Week 4, baseline
Change From Baseline in Triglycerides (TG) to Week 4.
Mean change at observation minus baseline
Time frame: Week 4, baseline
Change From Baseline in LDL at Week 6.
Mean change at observation minus baseline.
Time frame: Week 6, baseline
Change From Baseline in HDL at Week 6.
Mean change at observation minus baseline.
Time frame: Week 6, baseline
Change From Baseline in Total Cholesterol (TC) to Week 6.
Mean change at observation minus baseline.
Time frame: Week 6, baseline
Change From Baseline in Triglycerides (TG) at Week 6.
Mean change at observation minus mean baseline.
Time frame: Week 6 , baseline
Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk.
Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 \[best\] to greater than or equal to 14 \[worst\] for men; less than or equal to negative 2 \[best\] and greater than or equal to 17 \[worst\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.
Time frame: Week 4, baseline
| Milestone | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Started | 123 | 122 |
| Received treatment | 122 | 122 |
| Completed | 111 | 107 |
| Not completed | 12 | 15 |
| Withdrew: Adverse event | 11 | 15 |
| Withdrew: Did not receive treatment | 1 | 0 |
Number of subjects reaching dual goal of systolic blood pressure \<140 millimeters of mercury (mmHg) and diastolic blood pressue of \<90 mmHg and low density lipoprotein-cholesterol(LDL-C) \<100 milligrams per deciliter(mg/dL)
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With Blood Pressure (BP) <140/90 Millimeters of Mercury (mmHg) and Low Density Lipoprotein Cholesterol (LDL-C) <100 Milligrams Per Deciliter(mg/dL) at Week 6 | 11 | 80 |
Subjects achieving both the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC)-7 blood pressure goal of \<140/90 mmHg and the National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP) III Update low density lipoprotein-cholesterol (LDL-C) goal \<100 mg/dL at Week 4.
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With Blood Pressure of <140/90 mmHg and LDL-C <100 mg/dL at Week 4 | 6 | 73 |
Subjects achieving both JNC-7 blood pressure goal of \<140/90 mmHg and NCEP/ATP III LDL-C goal \<130 mg/dL at Week 4.
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 4. | 41 | 85 |
Subjects achieving both JNC-7 blood pressure goal of \<140/90 mmHg and NCEP/ATP III LDL-C goal \<130 mg/dL at Week 6.
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With BP <140/90 mmHg and LDL-C <130 mg/dL at Week 6. | 45 | 90 |
Subjects Who achieve a goal of LDL-C \< 100 mg/dL at Week 4.
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With LDL-C < 100 mg/dL at Week 4 | 8 | 96 |
Subjects Who achieve a goal of LDL-C \< 100 mg/dL at Week 6.
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With LDL-C < 100 mg/dL at Week 6 | 13 | 99 |
Subjects achieving BP goal of \<140/90 mmHg at week 4
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With BP < 140/90 mmHg at Week 4 | 84 | 87 |
Subjects achieving BP goal of \<140/90 mmHg at week 6
| participants | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Subjects With BP < 140/90 mmHg at Week 6 | 83 | 94 |
Mean at observation minus mean at baseline
| mmHg | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 4 in Systolic Blood Pressure (SBP). | -2.6 ± 12.1 | -1.5 ± 11.9 |
Mean at observation minus mean at baseline
| mmHg | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 4 in Diastolic Blood Pressure (DBP) | -1.5 ± 7.7 | -1.2 ± 8.8 |
Mean at observation minus mean at baseline measured in beats per minute (bpm).
| bpm | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 4 in Pulse Rate | -0.1 ± 8.2 | -0.9 ± 8.5 |
Mean change at observation minus mean baseline.
| mmHg | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 6 in Systolic Blood Pressure (SBP) | -1.0 ± 12.6 | -4.0 ± 11.0 |
Change from mean at observation minus mean at baseline
| mmHg | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 6 in Diastolic Blood Pressue (DBP) | -1.1 ± 7.1 | -1.7 ± 8.2 |
Mean at observation minus mean at baseline
| bpm | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 6 in Pulse Rate | 0.9 ± 8.1 | 1.1 ± 9.0 |
Change: mean of observation minus mean at baseline.
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline in LDL at Week 4. | -0.5 ± 23.0 | -47.8 ± 24.4 |
Mean change at observation minus baseline.
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline in High Density Lipoprotein (HDL) at Week 4. | 0.6 ± 5.8 | 0.6 ± 8.6 |
Mean change at observation minus baseline.
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change in Total Cholesterol (TC) From Baseline to Week 4. | 0.5 ± 23.5 | -55.9 ± 26.8 |
Mean change at observation minus baseline
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline in Triglycerides (TG) to Week 4. | 2.4 ± 73.2 | -45.7 ± 62.8 |
Mean change at observation minus baseline.
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline in LDL at Week 6. | 0.3 ± 24.8 | -49.2 ± 24.0 |
Mean change at observation minus baseline.
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline in HDL at Week 6. | 1.2 ± 8.2 | 0.4 ± 8.2 |
Mean change at observation minus baseline.
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline in Total Cholesterol (TC) to Week 6. | 3.7 ± 23.8 | -56.8 ± 28.4 |
Mean change at observation minus mean baseline.
| mg/dL | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline in Triglycerides (TG) at Week 6. | 11.6 ± 115.3 | -42.6 ± 67.3 |
Framingham prediction of absolute 10-year risk of CHD outcomes (MI or CHD death) are calculations based on total point score (range less than negative 3 \[best\] to greater than or equal to 14 \[worst\] for men; less than or equal to negative 2 \[best\] and greater than or equal to 17 \[worst\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol and systolic blood pressure calculated at Week 4. Mean at observation minus mean at baseline.
| score on scale | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 4 in Framingham Predicted Absolute 10-year Risk. | -0.3 ± 2.5 | -2.8 ± 3.3 |
Framingham prediction of absolute 10-year risk of Coronary Heart Disease (CHD) outcomes (myocardial infarction \[MI\] or CHD death) are calculations based on total point score (range less than negative 3 \[best\] to greater than or equal to 14 \[worst\] for men; less than or equal to negative 2 \[best\] and greater than or equal to 17 \[worst\] for women) of subject age, sex, current blood pressure treatment status, current smoking status, total cholesterol, high-density lipoprotein cholesterol, and systolic blood pressure calculated at Week 6. Mean at observation minus mean at baseline.
| score on scale | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Change From Baseline to Week 6 in Framingham Predicted Absolute 10-year Risk | -0.1 ± 2.9 | -2.9 ± 3.0 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Norvasc + TLC | — | 0/122 (0%) | 16/122 (13.1%) |
| Caduet + TLC | — | 0/122 (0%) | 7/122 (5.7%) |
| Event | Norvasc + TLC | Caduet + TLC |
|---|---|---|
| Oedema peripheralGeneral disorders | 8/122 | 3/122 |
| HypertensionVascular disorders | 5/122 | 3/122 |
| Urinary tract infectionInfections and infestations | 3/122 | 1/122 |
| Age, Customized(participants) | Norvasc + TLC | Caduet + TLC | Total |
|---|---|---|---|
| 18 to 64 years | 95 | 97 | 192 |
| > or = to 65 years | 27 | 25 | 52 |
| Sex: Female, Male(Participants) | Norvasc + TLC | Caduet + TLC | Total |
|---|---|---|---|
| Female | 56 | 65 | 121 |
| Male | 66 | 57 | 123 |
The record gives a start of Jan 2007, a primary completion of Apr 2008 and a completion of Apr 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →